Impedimed Limited (IPDQF)
OTHER OTC:IPDQF
IPDQF Stock Chart & Stats
$0.01
<$0.01(23.84%)
At close: 4:00 PM EST
$0.01
<$0.01(23.84%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.05
Previous CloseN/A
Volume1.78K
Average Volume (3M)5.35K
Market Cap
$21.50M
Enterprise Value$33.67M
Total Cash (Recent Filing)$18.85M
Total Debt (Recent Filing)$21.93M
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Aug 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,038,747,700
10 Day Avg. Volume16,058
30 Day Avg. Volume5,352
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)3.45
Price to Sales (P/S)5.55
P/FCF Ratio-4.52
Enterprise Value/Market Cap1.57
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit-40.47
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$0.03Price Target Upside200.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$11.67M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsAn 86.25% gross margin shows BIS product cost of goods sold are low relative to pricing, producing durable unit economics. That margin cushion supports sustained R&D and commercial investment, improving the chance of positive operating leverage as the installed base scales.
Recurring Installed-base RevenueThe business model combines upfront device sales with recurring consumables/software tied to an installed base, creating annuity-like revenue. This structural mix raises customer lifetime value and provides more predictable revenue streams as BIS adoption in clinical workflows grows.
Manageable LeverageA debt-to-equity ratio of ~0.71 indicates moderate leverage and balance-sheet capacity. This financial flexibility lowers near-term solvency risk and preserves options to fund commercialization, product development or targeted M&A without immediate distress over the coming months.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow, with free cash flow declining 20.73%, demonstrates the business is burning cash as it scales. Over a multi-month horizon this constrains funding for sales, service and R&D and increases reliance on external financing or dilutive capital raises if not improved.
Weak Operating ProfitabilityNegative EBIT and net margins despite strong gross margins indicate operating expenses outpace revenue. Structural cost or revenue-mix issues must be resolved to reach sustainable profitability; otherwise losses will persist and limit retained earnings and strategic flexibility.
Negative Return On EquityA negative ROE shows shareholder capital is not generating positive returns, reflecting structural earning shortfalls. This hinders the company’s ability to attract long-term equity investment, reduces reinvestment capacity, and limits prospects for dividends or buybacks in the medium term.
Impedimed Limited News
IPDQF FAQ
What was Impedimed Limited’s price range in the past 12 months?
Impedimed Limited lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
What is Impedimed Limited’s market cap?
Impedimed Limited’s market cap is $21.50M.
When is Impedimed Limited’s upcoming earnings report date?
Impedimed Limited’s upcoming earnings report date is Aug 27, 2026 which is in 136 days.
How were Impedimed Limited’s earnings last quarter?
Impedimed Limited released its earnings results on Feb 20, 2026. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of -$0.001 by -$0.003.
Is Impedimed Limited overvalued?
According to Wall Street analysts Impedimed Limited’s price is currently Undervalued.
Does Impedimed Limited pay dividends?
Impedimed Limited does not currently pay dividends.
What is Impedimed Limited’s EPS estimate?
Impedimed Limited’s EPS estimate is 0.
How many shares outstanding does Impedimed Limited have?
Impedimed Limited has 2,038,747,700 shares outstanding.
What happened to Impedimed Limited’s price movement after its last earnings report?
Impedimed Limited reported an EPS of -$0.004 in its last earnings report, missing expectations of -$0.001. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Impedimed Limited?
Currently, no hedge funds are holding shares in IPDQF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Impedimed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$0.03 (200.00% Upside)
$0.03 (200.00% Upside)
Blogger Sentiment
Bullish
IPDQF Sentiment 88%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $20.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.54%
12-Months-Change
Fundamentals
Return on Equity
-165.13%
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Impedimed Limited
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
IPDQF Stock 12 Month Forecast
Average Price Target
$0.03
▲(200.00% Upside)
Technical Analysis
Compumedics Limited
―
Uscom Limited
―
HeraMED Ltd.
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Ownership Overview
0.74% Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---